Press release

ApiFix Completes Financing to Prepare for Commercial Efforts in the United States

Sponsored by Businesswire

ApiFix Ltd., a leading motion-preservation scoliosis correction company,
today announced completion of its Series B equity financing. A new
US-based investor led the round with participation from existing

“We are extremely pleased to have Palm Tree IV as our new partner
leading this round of financing as we work toward FDA approval this year
and prepare for US commercialization of our MID-C System,” said Paul
Mraz, CEO for ApiFix Ltd. “It allows us to stay focused on our mission,
which is to ‘change the lives of scoliosis patients forever.’”

“Significant clinical data from treating patients over the past seven
years demonstrates the clinical benefits of our less-invasive,
non-fusion deformity correction system,” said ApiFix co-founder and
Chief Medical Officer, Yizhar Floman MD. “We are excited to be on the
cusp of broadly introducing a game-changing, patient-friendly treatment
into the lives thousands of children and their families.”

ApiFix’s Minimally Invasive Deformity Correction (MID-C) is a posterior
dynamic deformity correction system that enables surgeons to perform a
unique treatment providing permanent curve correction while retaining
spine flexibility, all via a minimally invasive surgical approach.
Patient recovery is relatively pain-free and is measured in days, not
months. The MID-C system acts as an “internal brace” with a patented
unidirectional, self-adjusting rod mechanism and motion-preserving
polyaxial joints, allowing additional post-operative correction over
time and is removable.

About ApiFix Ltd.

Founded in 2011, ApiFix Ltd. is a privately held medical device
company based in Misgav, ISRAEL and Boston, Massachusetts, USA and is a
portfolio company of The Trendlines Group Ltd. (SGX: 42T; OTCQX: TRNLY).
ApiFix is a leading motion-preservation scoliosis correction company
developing a unique platform technology that represents a disruptive
approach to spine deformity treatment. ApiFix’s Minimally Invasive
Deformity Correction (MID-C) system has CE Mark approval and is
available in Europe, Israel, Singapore and Canada. More information is
available at